



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2023
9th August 2023

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Security Symbol: IOLCP

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai- 400 001
Security Code: 524164

Subject: Press Release for Financial Results Q1 FY24

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 9th August 2023 with respect to financial results for the first quarter ended 30th June 2023.

Hope you will find the same in order.

Thanking You,

Yours faithfully,
For IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh
Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited

For immediate release

IOL Chemicals and Pharmaceuticals net profit grows 32% YoY

- Total income for Q1 FY24 stood at Rs. 570 crore at the same level of Rs.570 crore YoY
- EBITDA for Q1 FY24 at Rs. 80 crore as compared to Rs. 61 crore YoY
- Net profit for Q1 FY24 at Rs. 46 crore as compared to Rs. 35 crore YoY

09th August 2023, Ludhiana:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the first quarter ended June 30, 2023.

Q1FY24 Financial Highlights

(Rs in Crore)

Particulars	Q1FY24	Q1FY23	% YoY	Q4FY23
Total Income	570.24	570.16	-	595.93
EBITDA	79.92	61.17	30.6 %	104.51
EBITDA Margin (%)	14.0%	10.7%	330 bps	17.5%
PAT	46.21	34.89	32.4%	65.27
PAT Margin (%)	8.1%	6.1%	200 bps	11.0%

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director, said ***“We are pleased to report sustainable performance during the 1st quarter of FY24, tackling present challenges while positioning ourselves for forthcoming opportunities. We are hopeful for increased presence in regulatory markets as the Company got CEP for paracetamol. Additionally, with the commencement of Acetic Anhydride plant, focus on improved efficiencies, product mix and timely execution we are hopeful to generate strong cash flow”.***

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like Pain Management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.



IOL Chemicals And Pharmaceuticals Limited

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid, Acetyl Chloride and Acetic Anhydride.

The company is the World's largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.